MAP3K8 and post-transplant lymphoproliferative disease: Strikingly, this pathway is required for survival of PTLD as pharmacological IKK2 and TPL2 inhibition very efficiently blocked proliferation of PTLD cells and the corresponding LCL (Fig. 8c, d, respectively).